Spread the loveIn a remarkable advancement in cancer treatment, researchers from Shandong University have engineered a strain of Escherichia coli Nissle 1917, a well-known probiotic, to act as a ...

Affordability is a worthy goal, but a patient whose cancer just stopped responding to older treatment doesn't need a cheaper drug. She needs a better one.

Researchers developed a chip-based platform, “μPharma,” that rapidly predicts drug response through AI analysis for children ...

Scientists have engineered probiotic bacteria to act as tumor-seeking drug factories. In mice, these bacteria infiltrated tumors and produced a cancer-fighting drug right where it was needed. This ...

A new study sheds light on why promising cancer treatments can produce dramatically different results across patients.

According to a spokesperson for Neal Dunn the FAIC Act aims to guarantee that Medicare cancer patients have access to the ...

Novartis (NOVN) announces acquisition of experimental breast cancer drug SNV4818 for up to $3B. Stock dipped 0.94% on the news. Deal closes H1 2026.

The U.S. Food and Drug ​Administration on Friday approved Bristol ‌Myers Squibb's combination treatment for adults and ...

In this episode of The OncoloGIST, breast cancer oncologist and clinical researcher Dr Paolo Tarantino of Dana-Farber Cancer Institute reflects on how antibody-drug conjugates (AD ...

Novartis AG agreed to buy an experimental breast cancer drug from Synnovation Therapeutics for as much as $3 billion to bolster its oncology pipeline.

Former UVA School of Medicine assistant professors Tomasz Cierpicki and Jolanta Grembecka, now at the University of Michigan, say their newly approved leukemia drug is offering hope to patients. “We ...

UCSF scientists found a precise way to turn on cancer-fighting immune cells inside the body. This more potent form of CAR-T has the potential to treat many more cancers.